BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock Forecast & Price Target
BridgeBio Oncology Therapeutics, Inc. · NASDAQ
$8.85-0.13 (-1.45%)
15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 9 firms covering BridgeBio Oncology Therapeutics, Inc, 9 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $20.00 to $29.00, a moderate spread. The average target of $24.00 sits 171% above the current $8.85. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 0% this year and 0% next, consensus EPS building from about $-0.63 next quarter toward $-2.41 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 ratings
Strong Buy
Strong Buy00%
Buy9100%
Hold00%
Sell00%
Strong Sell00%
Based on 9 analysts giving stock ratings to BridgeBio Oncology Therapeutics, Inc.
As of Sep, 8 of 8 firms rate BBOT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
BBOT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.63
Range $-0.72 – $-0.49 · 10 analysts · +28% YoY
Next period, 10 analysts expect BridgeBio Oncology Therapeutics, Inc. to earn $-0.63 a share (range $-0.72 – $-0.49), versus $-0.49 a year earlier. Full-year consensus is $-2.68, growing to $-2.41 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 10 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering BridgeBio Oncology Therapeutics, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BBOT.
#1
David Nierengarten
Wedbush · Rank #66
Buy
$25.00+182.5% to target
Overall win rate
42%
+ Follow
#2
Andrew Berens
Leerink Partners · Rank #121
Buy
$41.00+363.3% to target
Overall win rate
56%
+ Follow
#3
RB
Robert Burns
HC Wainwright & Co. · Rank #199
Buy
$29.00+227.7% to target
Overall win rate
41%
+ Follow
#4
John Newman
Canaccord Genuity · Rank #409
Buy
$23.00+159.9% to target
Overall win rate
30%
+ Follow
#5
Matthew Biegler
Oppenheimer
Buy
$22.00+148.6% to target
Coverage
—
+ Follow
BBOT stock forecast FAQ
What is BBOT's average 12-month price target?+
The 9 analysts with a live target average $24.00 for BridgeBio Oncology Therapeutics, Inc. over the next 12 months, ranging from a $29.00 high to a $20.00 low.
Is BBOT stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 9 analyst ratings, 9 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for BBOT?+
The Street-high target is $29.00 (HC Wainwright & Co.), and the Street-low is $20.00 (Morgan Stanley). The average of all 9 active targets is $24.00.
How many Wall Street analysts cover BBOT?+
9 analysts have an active rating on BridgeBio Oncology Therapeutics, Inc., and 9 firms carry a live 12-month price target.
Who is the most accurate analyst covering BBOT?+
Among analysts who currently cover BBOT, David Nierengarten of Wedbush has the strongest overall Quantellect track record (Rank #66). Their current call is Buy with a $25.00 target.
What is BridgeBio Oncology Therapeutics, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.63 per share (range $-0.72 – $-0.49) across 10 analysts. Full-year EPS is projected at $-2.68, rising to $-2.41 the following year.
How much revenue is BridgeBio Oncology Therapeutics, Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading BBOT lately?+
As of Sep, 8 of 8 firms rate BBOT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BBOT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
Oppenheimer
